据报国药疫苗将授权於阿根廷生产
阿根廷媒体报道,中国国药加快其新冠疫苗在阿根廷本地生产的进度,国药於阿根廷当地的合作夥伴将是Hugo Sigman公司,後者将提供其Sinergium工厂生产国药疫苗,加上疫苗的包装也将在该国内进行,因此国药新冠疫苗将全程在阿根廷生产。
阿根廷重要政府官员称很快会发布合作协议,而阿根廷制药公司亦已与国药集团建立联系,可迅速开始生产。
报道指,Sigman公司将投资改造位於布省加林镇的工厂,预计随着工厂升级改造,加上来自中国的抗原材料,阿根廷将很快能达到每周可生产约一百万剂新冠疫苗的产量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.